Curriculum
|
Attendance 1 |
Module 1 |
Module 2 |
Attendance 2 |
Module 3 |
Module 4 |
Attendance 3 |
Total |
|
|
Timetable |
2019 |
2019 |
2019 |
2019 |
2019 |
2019-2020 |
2020 |
14 months |
|
Content |
CCL course + |
Topic 1 |
Topic 2 |
ESO course |
Topic 3 |
Topic 4 |
CCL course |
|
|
Workload |
25 hrs |
20 units |
30 units |
25 hrs |
30 units |
30 units |
25 hrs |
75 hrs |
|
Credits |
1 ECTS |
2 ECTS |
3 ECTS |
1 ECTS |
3 ECTS |
3 ECTS |
1 ECTS |
14 ECTS |
CCL: separate and specific seminar for Certificate of Competence in Lymphoma participants
IOSI course: join the course held by the Oncology Institute of Southern Switzerland (IOSI - Bellinzona, Switzerland)
ESO course: join sessions of the ESO Advanced Course on Leukaemia and Lymphoma (Lugano, Switzerland)
The extensiveness of the Module's programme is expressed in Units.
1 Unit equals to 3 hours of workload, consisting of a 30-minute lecture and 2,5 hours of additional reading.
For instance:
2 Units = 6 hours of workload = 60-minute lecture + 5 hours of additional reading.
| Seminar/Module | Topics |
Units |
Workload |
ECTS |
Comment |
|
Seminar 1: |
25 |
1 |
No exam | ||
| Programme will follow | |||||
| Module 1: Basic research, epidemiology and pathology of lymphoma |
Giancarlo Gaidano, Randy Gascoyne |
20 |
60 |
2 |
Test (40q) |
| Gene structure, gene expression and mutations in lymphoma [Ryan Morin] |
2 |
||||
| Micro RNAs and Lymphoma [George Calin] |
2 |
||||
| Signalling pathways [Ralph Küppers] |
2 |
||||
| Apoptotic pathways [Francesco Bertoni] |
2 |
||||
| Tumor suppressor genes and oncogenes [Laura Pasqualucci] |
2 |
||||
| Microenvironment [Pedro Farinha] |
2 |
||||
| Epigenetics [Daniel Mertens] |
2 |
||||
| Immune system and lymphoma [Mariagrazia Uguccioni] |
2 |
||||
| Epidemiology [Diego Serraino] |
2 |
||||
| Pathology (principles of the current classification) [Stefano Pileri] |
2 |
||||
|
Learning |
Participants will: |
||||
| Module 2: Principles of diagnostic, management and clinical trials |
Andrew Lister, Anton Hagenbeek, Mary Gospodarowicz |
30 |
90 |
3 |
test (60q) |
| Diagnostic procedures: | |||||
| - Diagnosis on lymph node biopsy, including knowledge on immunophenotyping, specific cytogenetics, molecular diagnostics, gene profiling etc. [Daphne de Jong] |
1 |
||||
| - Initial work-up (physical examination, bone-marrow biopsy, laboratory and imaging). Establishing the stage of disease, A or B [Silvia Montoto] |
1 |
||||
| Principles of treatment: |
|
||||
| - Chemo- and immune-chemotherapy, including autologous stem cell transplant [Jonathan W. Friedberg] |
2 |
||||
| - Antibodies,vaccines, PD1 / PDL1 [Anastasios Stathis] |
2 | ||||
| - Allogeneic stem cell transplant [Jakob Passweg] |
2 | ||||
| - Radiotherapy [Berthe Aleman] |
1 |
||||
| - Targeted treatment with e.g. antibody drug-conjugates, radio-immunotherapy , etc. [Julie M. Vose] |
1 |
||||
| - T-cell lymphomas [Julie M. Vose] |
1 |
||||
| - Targeted treatment with new compounds: small molecules beyond antibodies [Andrew Davies] |
1 |
||||
| Prognostic and predictive factors: |
|
||||
| - FLIPI/IPI [Laurie Sehn] |
1 |
||||
| - Molecular prognostic factors [Georg Lenz] |
1 |
||||
| - Imaging [Sally Barrington] |
2 |
||||
| Management of clinical trials: |
|
||||
| - Design and interpretation of clinical trials [Penny Bradbury] |
1 |
||||
| - Meta-analysis and systematic review [Dietrich Rothenbacher] |
1 |
||||
| - Planning and performance of clinical trials (introduction to good clinical practice) [Anastasios Stathis] |
1 |
||||
| - Development of a protocol: from the idea to the protocol writing [Anastasios Stathis] |
1 |
||||
| - Evaluation and publication of clinical trials [Bruce Cheson] |
1 |
||||
| - Sponsor responsibility [Cristiana Sessa] |
1 |
||||
| - Management of a clinical trial database [Liv Meert] |
1 |
||||
| - Cost evaluation and control, including funding [Gerhard Held] |
1 |
||||
| - Transfer of study results into clinical practice [James O. Armitage] |
1 |
||||
| Evaluation of treatment results: |
|
||||
| - Response criteria and follow-up schedule [Bruce Cheson] |
1 |
||||
| - Minimal residual disease [Davide Rossi] |
1 |
||||
| The challenge of translational research: | |||||
| - Integrating molecular biology with clinical trials [Kieron Dunleavy] |
1 |
||||
| - Management of biobanks [Peter Moeller] |
2 |
||||
| Learning objectives |
Participants will: • Acquire and develop effective skills to advance the practice of clinical research in lymphoma. • Acquire the capability of analysing and evaluating contemporary issues in clinical research and in good-clinical practice. • Update their knowledge concerning design and interpretation of clinical trials, systemic reviews and meta-analyses. • Acquire skills on how to manage a clinical trial. • Update their knowledge on how to manage lymphoma patients on an evidence-based approach and will be able to transfer the current evidence-based guidelines into daily clinical practice. • Acquire state-of-the-art knowledge as recommended by international experts and guidelines and treatment protocols developed nationally and internationally. • Learn about haematological diagnostic procedures (immunophenotyping). • Learn about imaging techniques and their indications in lymphoma. • Learn about distinct principles of therapy of lymphoid malignancies. • Update their knowledge concerning response evaluation, response criteria and follow-up schedules. |
||||
|
Seminar 2: |
25 |
1 |
No exam | ||
| Programme will follow | |||||
| Module 3: Lymphoma subtypes Part I: Mature B-cell neoplasms |
Emanuele Zucca, Julie M. Vose, Bertrand Coiffer |
30 |
90 |
3 |
Test (60q) |
| CLL/SLL/B-PLL (indolent): |
|
||||
| - Pathogenesis and B-cell signalling [Ralph Küppers] |
1 |
||||
| - First line treatment of CLL [Stephan Stilgenbauer] |
1 |
||||
| - Treatment of relapsed / refractory CLL [Manuela Hoechstetter] |
1 |
||||
|
- Chronic lymphocytic leukemia: |
1 |
||||
| Lymphoplasmacytic lymphoma / Waldenström´s Macroglobulinemia [Eva Kimby] |
1 |
||||
| - Light-chain amyloidosis [Bernhard Gerber] |
1 |
||||
| - Hairy cell leukaemia [Francesco Forconi] |
1 |
||||
| Follicular lymphoma: |
|
||||
| - Natural history of follicular lymphoma and unmet clinical needs [T. Andrew Lister] |
1 |
||||
| - Front-line treatment at relapse [Gilles Salles] |
1 |
||||
|
- Is there room for a non-chemotherapy based |
1 |
||||
| Marginal zone lymphoma (nodal and extranodal) (gastric and non-gastric MALT lymphoma, nodal marginal zone lymphoma, splenic marginal zone lymphoma): |
|
||||
| - MALT [Franco Cavalli] |
1 |
||||
| - Non-MALT [Davide Rossi] |
1 |
||||
| Mantle cell lymphoma [Martin Dreyling] |
2 |
||||
| Diffuse large B-cell lymphoma (agressive): |
|
||||
| - Treatment of localised DLBCL [Joseph M. Connors] |
1 |
||||
|
- Treatment of advanced-stage DLBCL |
2 |
||||
| - Relapsed and refractory DLBCL [Christian Gisselbrecht] |
1 |
||||
| - Primary mediastinal large B-cell lymphoma [Andrew Davies] |
1 |
||||
| - Burkitt lymphoma [Ian Magrath] |
1 |
||||
| Richter syndrome [Davide Rossi] |
1 |
||||
| Immunodeficiency associated lymphoma (EBV, HHV-8, HTLV-I, HIV, HCV) and post transplant [Kieron Dunleavy] |
2 |
||||
| Extranodal lymphoma (CNS, testes) [Andrès Ferreri] |
2 |
||||
| Primary cutaneous B-cell lymphoma [Werner Kempf] |
1 |
||||
| Clonal lymphoid populations of uncertain malignant potential |
1 |
||||
| Plasma cell disorders [Stefan Knop] |
2 |
||||
| Management of lymphoma in the elderly patient [Joseph M. Connors] |
1 |
||||
| Learning objectives (Mod 3 and 4) |
Participants will: • Acquire problem-solving-strategies through case discussions with respect to the individual and critical dimensions of treatment. • Broaden the clinical skills in diagnosing mature B-cell neoplasms, PTLD, T-cell and NK-cell neoplasms and Hodgkin lymphoma. • Be able to design and customise treatment plans for mature B-cell neoplasms PTLD, T-cell and NK-cell neoplasms and Hodgkin lymphoma. • Understand clinical differences in the pathological processes and treatment. • Be able to design and customise treatment plans for special subgroups of lymphoma patients. |
||||
| Module 4: Lymphoma subtypes Part II: PTLD, T-cell and NK-cell neoplasms and Hodgkin lymphoma |
Andreas Engert, Massimo Federico |
30 |
90 |
3 |
Test (60q) |
| PTLD [Ralf Ulrich Trappe] |
2 |
||||
| T-PLL and T-LGL [Dima El-Sharkawi] |
1 |
||||
| Adult T-cell leukaemia/lymphoma [Ruth Pettengell] |
1 |
||||
| Mycosis Fungoides, Sezary syndrome, cutaneous T-cell lymphoma [Silvia Alberti-Violetti] |
1 |
||||
| Peripheral T-cell lymphoma, non-cutaneous [Christian Gisselbrecht] |
2 |
||||
| Angioimmunoblastic T cell lymphoma and other nodal lymphoma of T follicular helper cell origin [Laurence de Leval] |
1 |
||||
| Anaplastic large cell lymphoma, ALK negative [Kerry Savage] |
1 |
||||
|
Anaplastic large cell lymphoma, ALD positive [Andrei Shustov] |
|||||
| EATL [Jan Delabie] | |||||
| Gamma/delta T cell lymphomas [Francine Foss] |
|||||
| Hodgkin lymphoma (HL): |
|
||||
| - Classical HL and nodular lymphocyte-predominant HL [Dennis Eichenauer] |
2 |
||||
| - Treatment of early-stage HL [Andreas Engert] |
1 |
||||
| - Treatment of advanced-stage HL [Bastian von Tresckow] |
1 |
||||
|
- Treatment of relapsed/refractory HL |
1 |
||||
| - Long-term complications of HL therapy [Stefano Luminari] |
1 |
||||
| Histiocytic and dendritic cell neoplasms [Stefano Pileri] |
2 |
||||
| Mastocytosis [Olivier Hermine] |
1 |
||||
| Gray zone lymphoma - preclinical aspects [Stefano Pileri] |
1 |
||||
| Gray zone lymphoma - clinical aspects [Clementine Sarkozy] |
1 |
||||
| Paediatric Hodgkin lymphoma [Monika Metzger] |
1 |
||||
| Paediatric non-Hodgkin lymphoma [Andishe Attarbaschi] |
1 | ||||
| Tumour Lysis syndrome and renal problems [Michele Spina] |
2 |
||||
| CNS Lymphomas [Andrès Ferreri] |
2 |
||||
| Lymphoma in pregnancy [Alden Moccia] |
1 |
||||
| Familiar lymphoma [Stefano Luminari] |
1 |
||||
| Learning objectives (Mod. 3 and 4) |
Participants will: • Acquire problem-solving-strategies through case discussions with respect to the individual and critical dimensions of treatment. • Broaden the clinical skills in diagnosing mature B-cell neoplasms, PTLD, T-cell and NK-cell neoplasms and Hodgkin lymphoma. • Be able to design and customise treatment plans for mature B-cell neoplasms PTLD, T-cell and NK-cell neoplasms and Hodgkin lymphoma. • Understand clinical differences in the pathological processes and treatment. • Be able to design and customise treatment plans for special subgroups of lymphoma patients. |
||||
| Seminar 3: Ulm, Germany 26-30 April 2020 |
25 |
1 |
Certificate |
||
| Programme will follow | |||||
Examination regulations (Module Tests and Certificate Examination)
At the end of each module participants have to pass a mandatory online test that has to be submitted to Ulm University. Only participants who passed the four tests will have access to the Certificate Exam at the end of the Programme.
Module Tests:
The written multiple-choice Module Test is deemed to have been passed if a minimum of 60% of the questions were answered correctly.
Module Tests are not graded and can be re-taken as often as necessary until the Test is passed.
Certificate Examination:
The Certificate Exam will be held using prepared Ulm University computers (not participants’ personal laptops) and it can only be taken at Seminar 3 of the Programme.
The written multiple-choice Certificate Examination is deemed to have been passed if a minimum of 60% of
the questions were answered correctly.
The grades are as follows:
1 = very good, 90% or more;
2 = good, 80% or more but less than 90%;
3 = satisfactory, 70% or more but less than 80%;
4 = sufficient, 60% or more but less than 70%;
5 = insufficient, less than 60%.
The Examination is also deemed to have been passed if the number of questions answered correctly by the participant falls short of the average examination result for all first-time examinees for this examination by no more than 10% provided that the examinee answered a minimum of 50% of the questions correctly.
Failed Examination may be re-taken twice but only within the time of attendance of Seminar 3, or during the next Programme Seminar of the following cohort.
Follow us